… survival, including enzalutamide and abiraterone, two new-… with abiraterone and 25% of
those treated with enzalutamide … of resistance to abiraterone and enzalutamide, and to discuss …

… system for treatment with abiraterone and enzalutamide. Only patients that received
sequential therapy with abiraterone-to-enzalutamide or enzalutamide-to-abiraterone (without any …

… abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer
… androgen-signaling–targeted inhibitor (abiraterone or enzalutamide). The trial was approved …

… in pre- and postdocetaxel settings in castration-resistant prostate cancer (CRPC) … of abiraterone
and enzalutamide with respect to OS and PFS. In the predocetaxel setting, enzalutamide …

… Our results demonstrated that enzalutamide was more efficacious than abiraterone for
patients with metastatic castration-resistant prostate cancer, but was associated with a …

… Combining abiraterone with enzalutamide would not inhibit reactivation of AR independent
… for cancers more likely to benefit from the combination of enzalutamide and abiraterone, we …

… of abiraterone acetate and enzalutamide in advanced CRPC. Our results show that in a
pre-docetaxel setting, enzalutamide … that enzalutamide may outperform AA with abiraterone in …

… ABSTRACT- Purpose: To compare the effectiveness and safety between abiraterone and
enzalutamide in the treatment of patients with metastatic castration-resistant prostate cancer (…

… and the second trial, which included enzalutamide, allocated 533 to the control group …
enzalutamide and abiraterone acetate were administered concurrently compared with abiraterone …

5000 Background: Co-targeting the androgen receptor (AR) and paracrine androgen biosynthesis
in mCRPC may be more effective than either alone. This study aims to evaluate safety…